Efficacy and tolerability of oxaliplatin plus irinotecan 5-fluouracil and leucovorin regimen in advanced stage colorectal cancer patients pretreated with irinotecan 5-fluouracil and leucovorin

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 6, 2005, Pages 565-569

  Stathopoulos, George P ^a,b   Rigatos, Sotiris K ^a   Stathopoulos, John G ^a   Xynotroulas, John P ^a   Dimou, Evangelini ^a  

^a Errikos Dunant Hospital   (Greece)

^b NONE   (Greece)

Author keywords

5 Fluorouracil; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

ANTIEMETIC AGENT; DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; GRANULOCYTE COLONY STIMULATING FACTOR; IRINOTECAN; ONDANSETRON; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ALLERGY; ANEMIA; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; COMBINED MODALITY THERAPY; DEXAMETHASONE; DIARRHEA; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LIFE TABLES; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; PERIPHERAL NERVOUS SYSTEM DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 29044441507     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/01.coc.0000182407.09593.a9     Document Type: Article

References (29)

1. Moertel CG. Chemotherapy of gastrointestinal cancer. In: Tajnon HJ, Staquet MJ, eds. Recent Advances in Cancer Treatment. New York: Raven Press; 1997:311-323.
2. Moertel CG. Chemotherapy for colorectal cancer. N Engl J Med. 1994;330:1136-1142.
3. Francini GP, Lorenzini L. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology. 1994;106:899-904.
4. Wolmark N, Rockette H, Fisher B, et al. The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy of primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-03. J Clin Oncol. 1993;11:1879-1887.
5. Sargent DJ, Niedzwiecki D, O'Connell MJ, et al. Recommendation for caution with irinotecan, fluorouracil and leucovorin for colorectal cancer. N Engl J Med. 2001;345:144-145.
6. Cunningham D, Pyrhonene S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet. 1998;352:1413-1418.
7. Rougier P, van Custem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet. 1998;352:1407-1412.
8. De Gramont A, Vignond J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-h continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer. 1997;33:214-219.
9. Carufi C, Brienza S, Pugliese P, et al. Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs. 2000;11:495-501.
10. Giaccheti S, Perpoint B, Zidani R, et al. Phase III multicentre randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18:136-147.
11. De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000;18:2938-2947.
12. Douillard JY, Sobrero A, Carnaghi C, et al. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann Oncol. 2003;14:ii7-ii12.
13. Sorbye H, Glimelius B, Berglund A, et al. Multicenter phase II study of nordic fluorouracil and folinic acid bolus schedule combined with oxaliplatin as a first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2004;22:31-38.
14. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22:23-30.
15. WHO Handbook for reporting results of Cancer treatment. Geneva, Switzerland: World Health Organization, 1979.
16. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol. 1992;10:896-903.
17. De Gramont A, Bosset JF, Milan C, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808-815.
18. Scheithawer W, Rosen H, Kornek GV, et al. Randomized comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J. 1993;306:752-755.
19. Bleiberg H. Role of chemotherapy for advanced colorectal cancer: new opportunities. Semin Oncol. 1996;23:42-50.
20. Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as a first-line treatment for metastatic colorectal cancer: a multicentre randomized trial. Lancet. 2000;355:1041-1047.
21. Saltz LB, Cox JV, Blanke C, et al. Irinotecan Study Group: irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med. 2000;343:905-914.
22. Comella P, Crucitta E, De Vita F, et al. Addition of either irinotecan or methotrexate to bolus 5-fluorouracil and high-dose folinic acid every 2 weeks advanced colorectal carcinoma: a randomized study by the Southern Italy Cooperative Oncology Group. Ann Oncol. 2002;13:866-873.
23. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen Panel. Biochem Pharmacol. 1996;52:1855-1865.
24. Wasserman E, Cuvier C, Lokeic F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol. 1999;17:1751-1759.
25. Scheithawer W, Kornek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer. J Clin Oncol. 1999;17:902-906.
26. Rothenberg ML. Efficacy of oxaliplatin in the treatment of colorectal cancer. Oncology. 2000;14:9-14.
27. Souglakos J, Mavroudis D, Kakolyris, et al. Triplet combination with irinotecan plus oxaliplatin plus continuous infusion fluorouracil and leucovorin as first-line treatment in metastatic colorectal cancer: a multicenter phase II trial. J Clin Oncol. 2002;20:2651-2657.
28. Scheithawer W, Kornek GV, Raderer M, et al. Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2003;21:1307-1312.
29. Tournigand C, André T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomised GERCOR study. J Clin Oncol. 2004;22:229-237.